Growing Through Challenges? – Aquestive Therapeutics Inc. (NASDAQ: AQST)

0
28

The Vanguard Group, Inc. recently announced the acquisition of new stake in Aquestive Therapeutics Inc. (NASDAQ:AQST). The institutional investor has increased its shareholding in the Healthcare company by 5.05% to 0.62 million shares with purchase of 29907.0 shares. This fresh investment now brings its stake to 1.85% valued currently at $3.02 million. In addition, JPMorgan Securities LLC (Investme. raised its holdings by 95381.0 to 0.41 million shares. And Renaissance Technologies LLC has lifted its position by 272.22% or 0.22 million shares – to 0.29 million shares.

With over 0.53 million Aquestive Therapeutics Inc. (AQST) shares trading Tuesday and a closing price of $4.13 on the day, the dollar volume was approximately $2.2 million. The shares have shown a negative weekly performance of -9.93% and its price on 07/14/20 lost nearly -2.02%. Currently, there are 33.57M common shares owned by the public and among those 29.53M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for AQST have a consensus price objective of $17.50. The analysts have set the share’s price value over the next 12 months at a high of $31.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Aquestive Therapeutics Inc. stock is 1.80 for the next 12 months. But an upside of 86.68% will see the stock hit the forecast high price target while mean target price for the stock is $16.50.

Insiders at the company have transacted a total of 51 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 30 of these insider trades were purchases, accounting for 179,458 shares. Insider sales of the common stock occurred on 21 occasions, with total insider shares sold totaling 272,148 shares.

The top 3 mutual fund holders in Aquestive Therapeutics Inc. are iShares Russell 2000 ETF, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu. iShares Russell 2000 ETF owns 0.38 million shares of the company’s stock, all valued at over $1.85 million. The company sold 9675.0 shares recently to bring their total holdings to about 1.13% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 0.72% of the shares outstanding.

Shares of Aquestive Therapeutics Inc. (NASDAQ: AQST) opened at $4.18, down -$0.03 from a prior closing price of $4.21. However, the script later closed the day at $4.13, down -2.02%. The company’s stock has a 5-day price change of -9.93% and 10.00% over the past three months. AQST shares are trading -29.12% year to date (YTD), with the 12-month market performance down to -0.60% lower. It has a 12-month low price of $1.41 and touched a high of $10.00 over the same period. Currently, 0.53 million shares have been traded, compared to an average intraday trading volume of 1.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.04%, -19.85%, and -8.77% respectively.

Institutional ownership of Aquestive Therapeutics Inc. (NASDAQ: AQST) shares accounts for 52.80% of the company’s 33.57M shares outstanding. Mutual fund holders own 42.08%, while other institutional holders and individual stakeholders account for 46.38% and 4.74% respectively.

It has a market capitalization of $146.64M. The earnings-per-share (ttm) stands at -$2.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.87% over the week and 6.85% over the month.

Analysts forecast that Aquestive Therapeutics Inc. (AQST) will achieve an EPS of -$0.43 for the current quarter, -$0.4 for the next quarter and -$1.36 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.48 while analysts give the company a high EPS estimate of -$0.35. Comparatively, EPS for the current quarter was -$0.82 a year ago. Earnings per share for the fiscal year are expected to increase by 11.80%, and 17.60% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Aquestive Therapeutics Inc. (AQST) as a “Strong Buy” at a consensus score of 1.80. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the AQST, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on April 22, 2019, with the firm’s price target at. Lake Street coverage for the Aquestive Therapeutics Inc. (AQST) stock in a research note released on January 03, 2019 offered a Buy rating with a price target of $14. RBC Capital Mkts was of a view on August 20, 2018 that the stock is Outperform, while JMP Securities gave the stock Mkt Outperform rating on August 20, 2018, issuing a price target of $29.

LEAVE A REPLY

Please enter your comment!
Please enter your name here